NEW STUDY ON LUTEMAX 2020 SUPPORTING VISION FEATURED IN EXPERIMENTAL EYE RESEARCH JOURNAL

NEW STUDY ON LUTEMAX 2020 SUPPORTING VISION FEATURED IN EXPERIMENTAL EYE RESEARCH JOURNAL

The unique findings of a study on macular carotenoids from Lutemax 2020 conducted by the University of Georgia are the subject of a new paper Serum and Retinal Response to Three Different Doses of Macular Carotenoids Over 12 Weeks of Supplementation published in the July issue of Experimental Eye Research—the official journal of the International Society of Eye Research.

The macular carotenoids—lutein, RR- and RS (meso)-zeaxanthin—have been shown to have neuroprotective and visual performance benefits once deposited in retinal tissue.  The concentration of the three macular carotenoids in the macula is usually measured and expressed in terms of macular pigment ocular density (MPOD). Improvements in MPOD serum have been linked with potential improvements in visual function.

LAMA—an acronym for Lutein, Vision and Mental Acuity—is a group of studies showing the benefits of all three macular carotenoids from Lutemax 2020.  

“The great thing about the LAMA studies is that they show specific benefits from different doses of lutein and RR- and RS(meso)-zeaxanthin so formulators can adapt for the needs of specific target groups,” said Abhijit Bhattacharya, President, OmniActive Health Technologies. “The macular carotenoids have shown significant visual and neuroprotective benefits and OmniActive has sponsored the LAMA studies to explore and highlight the distinct benefits of Lutemax 2020 with a proprietary combination of all three macular carotenoids.”

This study—LAMA I—was a randomized, double-blind, placebo-controlled study in young, healthy subjects supplementing with three different doses of macular carotenoids, specifically lutein and zeaxanthin isomers (RR- and RS(meso)-zeaxanthin) from Lutemax 2020 at 6 and 1.2 mg, 10 and 2 mg and 20 and 4 mg, respectively. Within two weeks, there was a statistically significant increase in serum lutein and zeaxanthin concentrations at all three doses. More importantly, in 8 weeks, the 10 and 20 mg doses resulted in a statistically significant increase over placebo in MPOD. Furthermore, all three doses showed a sustained and significant increase over placebo in MPOD within 12 weeks. Even at the lowest dose, supplementation resulted in a significant increase over placebo in MPOD much sooner than what has been predicted by previous findings from other studies. Additionally, there was an improvement in the spatial profile of macular pigment where the greatest gains in optical density were shown in the very center of the macula, where the highest risk of photo-oxidative damage exists. “LAMA I is the first study to show supplementation with all three macular carotenoids—lutein, RR- and RS-zeaxanthin—resulted in rapid retinal response,” said James M. Stringham, Ph.D., University of Georgia. “This study further demonstrates the important role of lutein and zeaxanthin isomers in eye health.”

For more information on OmniActive’s ingredients or science, please contact Lynda Doyle at l.doyle@omniactives.com.

About Experimental Eye Research The primary goal of Experimental Eye Research is to publish original research papers on all aspects of experimental biology of the eye and ocular tissues that seek to define the mechanisms of normal function and/or disease. Studies of ocular tissues that encompass the disciplines of cell biology, developmental biology, genetics, molecular biology, physiology, biochemistry, biophysics, immunology or microbiology are most welcomed.

About University of Georgia

Incorporated in 1785, The University of Georgia (UGA) is the state's oldest, most comprehensive, and most diversified institution of higher education. Its motto, "to teach, to serve, and to inquire into the nature of things," reflects the university's integral and unique role in the conservation and enhancement of the state's and nation's intellectual, cultural, and environmental heritage. UGA’s research department encourages and supports innovative interdisciplinary research, scholarship and creative activities that contribute to the physical, emotional and economic well-being of the people of Georgia, the nation and the world. Through partnerships and collaborations, we seek to share knowledge, increase innovation, and deliver the products of our research to the marketplace.

About OmniActive Health Technologies, Inc.

OmniActive Health Technologies (www.omniactives.com) offers a range of quality ingredients, which are innovative and scientifically validated for dietary supplementation, nutritional fortification, functional food/beverage, coloring, flavor enhancement and personal care applications. The company addresses complex challenges for customers in the dietary supplement, food and beverage space using technology-driven, sustainable solutions with application support within a global regulatory framework. Whether looking for a new ingredient to add to a finished product, or an ingredient solution to enhance an existing ingredient, you will find unmatched innovation at OmniActive.

Core products include carotenoids, plant extracts and specialty functional ingredients. OmniActive leverages international R&D strengths to deploy an array of state-of-the-art manufacturing technologies in extraction, purification, isolation and delivery of nutritional actives. The company’s manufacturing operations are located at multiple sites in India and are cGMP and HACCP system compliant.

 

LUTEMAX 2020 is a trademark of OmniActive Health Technologies Ltd.

go back to PRESS RELEASES